Xencor Inc (XNCR) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.

Total Cash From Operating Activities Chart for Xencor Inc

Xencor Inc (XNCR) operating cash flow for FY2025 was USD -135.1M. Xencor Inc's operating cash flow moved from USD -1.1M in 2011 to USD -135.1M in 2025 over 14 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.70B
Implied Share Price
$22.85
Enterprise Value
$1.52B
Revenue (TTM)
$104.97M
EBITDA
-$205.90M
Profit Margin
-155.59%
Trailing P/E
—
Forward P/E
68.03
Price/Book (MRQ)
3.58
Price/Sales (TTM)
16.18
EV/EBITDA
-17.27
EV/Revenue
14.45
Dividend Yield
—
Book Value
$6.77
Free Cash Flow (FY2025)
-$138.27M
Free Cash Flow Yield
-8.14%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.